FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-02									
Estimated average burden									
hours per response:	0.5								

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  RANIERI RICHARD J					2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC [ NBIX ]							ck all application of the character of t	,	10% Ov Other (s	vner
(Last) (First) (Middle)  NEUROCRINE BIOSCIENCES, INC.  12790 EL CAMINO REAL				0	3. Date of Earliest Transaction (Month/Day/Year) 01/11/2007						Sr.	VP, Human I		liaabla	
(Street) SAN DIEGO CA 92130				4	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	dividual or Joint/Group Filing (Check Applicable )  K Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S		(Zip)	) Oprivati	vo S	ocuritio	- A c	equired D	isnosad (	of or Re	neficially	Owned			
1. Title of Security (Instr. 3)  2. Transar Date (Month/Date)				Transacti	ction 2A. Deemed Execution Date,			3. Transacti Code (Ins	str. (A) or		ed (A) or str. 3, 4 and 5	5. Amoun	s Form lly (D) ollowing (I) (I	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	cise (Month/Day/Year) ve	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	4. Transaction Code (Instr. 8)		er of es I (A) sed str. 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Stock Option <sup>(1)</sup>	\$11.44	01/11/2007		A		100,000		01/11/2008	01/11/2014	Common Stock	100,000	\$11.44	100,000	D	
Restricted Stock Unit	(2)	01/11/2007		A		58,000		(3)	(3)	Common Stock	58,000	\$0	58,000	D	

### **Explanation of Responses:**

- 1. Represents option of which 1/3 of the shares underlying the option becomes vested and exercisable on January 11, 2008, January 11, 2009 and January 11, 2010, respectively.
- 2. Each restricted stock unit represents a contingent right to receive one share of Neurocrine Common Stock
- 3. The restricted stock units will vest annually at 1/3 of the units vesting on February 11, 2008, January 11, 2009 and January 11, 2010, respectively.

### Remarks:

Margaret E. Valeur-Jensen, By 01/16/2007 Power of Attorney

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.